Global Kaposi Sarcoma Market: Patent Expiry of Blockbuster Drugs to Open up Lucrative Avenues in Cancer Therapies, notes TMR
The global Kaposi sarcoma (KS) market is extremely consolidated with the top two players accounting for a combined share of almost 50% in 2015, finds Transparency Market Research (TMR). These companies are Johnson & Johnson and Merck & Co. Inc. Currently, the share of regional vendors, such as Sun Pharmaceutical Industries Limited, is noticeably low; however, in the coming years, their regional shares are anticipated to augment considerably, notes TMR. Owing to the large-scale patent expiry of numerous blockbuster drugs, particularly in the U.S., the market will expectedly witness several new entrants in the coming years. A significant number of these companies will be focusing on developing generics, unlocking a wealth of opportunities for leading drug makers.
Key strategies adopted by companies include partnerships and acquisitions; several market players are collaborating with prominent companies for developing new products with enhanced efficacy. The global Kaposi sarcoma market is anticipated to expand at a modest CAGR of 2.2% from 2016 to 2024. The market stood at US$118.5 mn in 2015 and is expected to reach US$143.2 mn by 2024.
Chemotherapy Gaining Ground as Safe Treatment for Containing Kaposi Sarcoma
Geographically, the major regional markets for Kaposi sarcoma are Europe, North America, Asia Pacific, the Middle East & Africa (MEA), and Latin America. Of these, the Middle East and Africa market is projected to exhibit the most promising growth. The substantial demand for Kaposi sarcoma therapies is driven by its high prevalence and the increasing incidence of AIDS-induced Kaposi sarcoma in many parts of Eastern Africa.
Based on treatment method, the Kaposi sarcoma market is segmented into antiretroviral therapy, immunotherapy, and chemotherapy. Of these, the chemotherapy segment is expected to rise at a strong CAGR over the forecast period. The growing popularity of the treatment protocol is driven by its increased efficacy to contain cancer that has spread to multiple areas of the patient’s body. The treatment is also found to be effective in improving the quality of life in patients with classic or endemic Kaposi sarcoma.
Increasing Incidence Epidemic Kaposi Sarcoma to Boost Uptake of Antiretroviral Therapies
Since Kaposi sarcoma is one of the most common AIDS-defining malignancies, the increasing number of people who are HIV-positive has increased the incidence of AIDS-associated Kaposi sarcoma. The increasing efficiency of highly active antiretroviral therapy (HAART) in the treatment of epidemic or AIDS-related KS has boosted the growth of the market. The popularity of antiretroviral therapy (ART) as the key treatment modality to improve overall health and survival rate among AIDS-related KS is expected to fuel the market.
The increasing rate of organ transplant procedures has increased the vulnerability of patients to Kaposi sarcoma cancer. This is another crucial factor driving the Kaposi sarcoma market in various regions. The rising incidence of Kaposi sarcoma associated herpesvirus (KSHV) infection among patients who have undergone organ transplants is expected to spur the demand for KS treatments.
However, the high cost of patented cancer drugs restrains patients especially in low- and middle-income countries to avail treatments, thereby hindering the growth of the market to an extent. On the other hand, the expected arrival of several generics and the soaring preference for chemo drugs among immunocompetent patients are expected to fuel the market over the forecast period. In addition, advancement in specific biomarkers in diagnosing KS is expected to open up lucrative market in the coming years.
The study presented here is based on a report by Transparency Market Research (TMR) titled “Kaposi Sarcoma Market (Treatment - Chemotherapy (Liposomal Anthracyclines and Alkaloids), Immunotherapy, and HAART); Distribution Channel - Hospitals, Cancer Research Institutes, Multispecialty Clinics, and Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”
The global Kaposi sarcoma market is segmented based on
- Liposomal Anthracyclines
- Distribution Channel
- Cancer Research Institutes
- Multispecialty Clinics
- Ambulatory Surgical Centers
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South African Republic
- Rest of Middle East and Africa
- North America
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
7 of 10 large enterprizes view our ToC to take the right decision.View Report ToC